drugset
drugset / Trial / NCT05712538

Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.

NCT05712538 ↗

Phase 1 Completed 39 enrolled Arcturus Therapeutics, Inc. Novotech CRO · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Determine the safety, tolerability and pharmacokinetics of single doses of ARCT-032 in healthy adult subjects (Phase 1) and of two doses in Adults with Cystic Fibrosis (Phase 1b).

Timeline

Start
2023-02-15
Primary completion
2024-07-29
Completion
2024-07-29

Drugs

EvaluationDrugModalityDoseRoute
Subject ARCT-032 Messenger RNA (mRNA) — Inhaled

Indications

cystic fibrosis